PAVmed (NASDAQ:PAVM – Free Report) had its price objective upped by Ascendiant Capital Markets from $19.00 to $19.50 in a research note published on Monday,Benzinga reports. They currently have a buy… [+2123 chars]...
Read morePAVmed (NASDAQ:PAVM – Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of… [+1717 chars]...
Read more